PD
PHAT icon

Point72 (DIFC)’s Phathom Pharmaceuticals PHAT Stock Holding History

Point72 (DIFC)’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,951
Closed -$15.8K – 1977
2024
Q4 		$15.8K Buy
+1,951
New +$24.2K ﹤0.01% 1293

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Point72 (DIFC)'s PHAT Position: Q1 2025 in Review

Point72 (DIFC) sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 1,951 shares — an estimated $15.8K sold.

Point72 (DIFC) first reported a position in PHAT in Q4 2024 and held it in 1 quarter. The position peaked at $15.8K in Q4 2024. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

  • Point72 (DIFC) reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 1,951 Phathom Pharmaceuticals shares in Q1 2025, an estimated $15.8K.
  • Point72 (DIFC) first reported a position in Phathom Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Point72 (DIFC)'s Phathom Pharmaceuticals position peaked at $15.8K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.